Cardiff Oncology, Inc. SEC filings CRDF
Cardiff Oncology, Inc. has 1,001 filings in SEC EDGAR's recent list, going back to May 23, 2012. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 27, 2026 (officer or director change, bylaw or fiscal year change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 13, 2025 | — |
| CORRESP | Letter to the SEC | May 12, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 6, 2025 | — |
| EFFECT | Filing | Apr 25, 2022 | — |
| CORRESP | Letter to the SEC | Apr 21, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 14, 2022 | — |
| EFFECT | Filing | Jul 10, 2020 | — |
| CORRESP | Letter to the SEC | Jul 9, 2020 | — |
| UPLOAD | Letter from the SEC | Jul 2, 2020 | — |
| D | Filing | Jun 23, 2020 | — |
| EFFECT | Filing | Jun 2, 2020 | — |
| D | Filing | Jun 1, 2020 | — |
| UPLOAD | Letter from the SEC | May 29, 2020 | — |
| CORRESP | Letter to the SEC | May 29, 2020 | — |
| D | Filing | May 21, 2020 | — |
| D | Filing | Apr 14, 2020 | — |
| EFFECT | Filing | Nov 13, 2019 | — |
| UPLOAD | Letter from the SEC | Nov 12, 2019 | — |
| CORRESP | Letter to the SEC | Nov 12, 2019 | — |
| D | Filing | Oct 30, 2019 | — |
| EFFECT | Filing | Sep 10, 2019 | — |
| CORRESP | Letter to the SEC | Sep 6, 2019 | — |
| UPLOAD | Letter from the SEC | Sep 6, 2019 | — |
| D | Filing | Aug 28, 2019 | — |
| EFFECT | Filing | Jul 1, 2019 | — |
| UPLOAD | Letter from the SEC | Jun 27, 2019 | — |
| CORRESP | Letter to the SEC | Jun 27, 2019 | — |
| EFFECT | Filing | May 21, 2019 | — |
| CORRESP | Letter to the SEC | May 21, 2019 | — |
| D | Filing | May 20, 2019 | — |
| UPLOAD | Letter from the SEC | May 20, 2019 | — |
| CORRESP | Letter to the SEC | May 10, 2019 | — |
| UPLOAD | Letter from the SEC | May 9, 2019 | — |
| D | Filing | Apr 10, 2019 | — |
| EFFECT | Filing | Mar 11, 2019 | — |
| CORRESP | Letter to the SEC | Mar 8, 2019 | — |
| CORRESP | Letter to the SEC | Mar 6, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 25, 2019 | — |
| EFFECT | Filing | Jun 7, 2018 | — |
| CORRESP | Letter to the SEC | Jun 5, 2018 | — |
| CORRESP | Letter to the SEC | Jun 5, 2018 | — |
| UPLOAD | Letter from the SEC | May 18, 2018 | — |
| EFFECT | Filing | Dec 14, 2017 | — |
| CORRESP | Letter to the SEC | Dec 13, 2017 | — |
| CORRESP | Letter to the SEC | Dec 13, 2017 | — |
| CORRESP | Letter to the SEC | Nov 17, 2017 | — |
| UPLOAD | Letter from the SEC | Nov 7, 2017 | — |
| RW | Filing | Oct 31, 2017 | — |
| D | Filing | Jul 24, 2017 | — |
| 25-NSE | Delisting notice | May 30, 2017 | — |
| CT ORDER | Filing | May 19, 2017 | — |
| EFFECT | Filing | Jun 13, 2016 | — |
| CORRESP | Letter to the SEC | Jun 10, 2016 | — |
| CORRESP | Letter to the SEC | Jun 9, 2016 | — |
| UPLOAD | Letter from the SEC | Jun 9, 2016 | — |
| EFFECT | Filing | Nov 30, 2015 | — |
| CORRESP | Letter to the SEC | Nov 24, 2015 | — |
| UPLOAD | Letter from the SEC | Nov 24, 2015 | — |
| CT ORDER | Filing | Jul 16, 2014 | — |
| CT ORDER | Filing | Aug 27, 2013 | — |
| CT ORDER | Filing | Jun 14, 2013 | — |
| EFFECT | Filing | Feb 12, 2013 | — |
| EFFECT | Filing | Feb 4, 2013 | — |
| D | Filing | Dec 7, 2012 | — |
| DEFR14A | Defr 14a | Oct 19, 2012 | — |
| CERTNAS | Auto-generated paper document | May 29, 2012 | — |
| EFFECT | Filing | May 29, 2012 | — |
| CORRESP | Letter to the SEC | May 29, 2012 | — |
| CORRESP | Letter to the SEC | May 29, 2012 | — |
| CORRESP | Letter to the SEC | May 24, 2012 | — |
| CORRESP | Letter to the SEC | May 24, 2012 | — |
| CORRESP | Letter to the SEC | May 23, 2012 | — |
| CORRESP | Letter to the SEC | May 23, 2012 | — |
| 8-A12B | Registration/listing of securities on a national securities exchange | May 23, 2012 | — |
Showing 74 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CRDF (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1213037
- Former names
- Trovagene, Inc. (until May 7, 2020); TrovaGene Inc. (until Mar 4, 2013); XENOMICS INC (until Jun 3, 2009); USED KAR PARTS INC (until Jun 30, 2004)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.